Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management

Peter A. McCullough, Thomas M. Beaver, Elliott Bennett-Guerrero, Michael Emmett, Gregg C. Fonarow, Abhinav Goyal, Charles A. Herzog, Mikhail Kosiborod, Biff F. Palmer

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The plasma pool of potassium is a partial reflection of the overall body, transient cellular shifts, and potassium elimination regulated by the kidneys. Potassium concentrations elevating above the upper limit of normal (. 5.0 mEq/L) have become more common in cardiovascular practice due to the growing population of patients with chronic kidney disease and the broad applications of drugs that modulate potassium excretion by either reducing production of angiotensin II (angiotensin-converting enzyme inhibitors, direct renin inhibitors, beta-adrenergic receptor antagonists), blocking angiotensin II receptors (angiotensin receptor blockers), or antagonizing the action of aldosterone on mineralocorticoid receptors (mineralocorticoid receptor antagonists). In addition, acute kidney injury, critical illness, crush injuries, and massive red blood cell transfusions can result in hyperkalemia. Progressively more severe elevations in potassium are responsible for abnormalities in cardiac depolarization and repolarization and contractility. Untreated severe hyperkalemia results in sudden cardiac death. Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects. This review explores hyperkalemia as a complication in cardiovascular patients and highlights new acute, chronic, and preventative oral therapies (patiromer calcium, cross-linked polyelectrolyte, ZS-9) that could potentially create a greater margin of safety for vulnerable patients with combined heart and kidney disease.

Original languageEnglish (US)
Pages (from-to)11-23
Number of pages13
JournalReviews in Cardiovascular Medicine
Volume15
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Hyperkalemia
Potassium
Dietary Potassium
Calcium Gluconate
Mineralocorticoid Receptor Antagonists
Mineralocorticoid Receptors
Erythrocyte Transfusion
Angiotensin Receptors
Sodium Bicarbonate
Adrenergic Antagonists
Sorbitol
Albuterol
Angiotensin Receptor Antagonists
Ion Exchange
Receptors, Adrenergic, beta
Sudden Cardiac Death
Kidney Diseases
Patient Safety
Acidosis
Aldosterone

Keywords

  • Cardiovascular effects of kidney disease
  • Chronic kidney disease
  • Hyperkalemia
  • Potassium concentration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Acute and chronic cardiovascular effects of hyperkalemia : New insights into prevention and clinical management. / McCullough, Peter A.; Beaver, Thomas M.; Bennett-Guerrero, Elliott; Emmett, Michael; Fonarow, Gregg C.; Goyal, Abhinav; Herzog, Charles A.; Kosiborod, Mikhail; Palmer, Biff F.

In: Reviews in Cardiovascular Medicine, Vol. 15, No. 1, 2014, p. 11-23.

Research output: Contribution to journalArticle

McCullough, PA, Beaver, TM, Bennett-Guerrero, E, Emmett, M, Fonarow, GC, Goyal, A, Herzog, CA, Kosiborod, M & Palmer, BF 2014, 'Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management', Reviews in Cardiovascular Medicine, vol. 15, no. 1, pp. 11-23. https://doi.org/10.3909/ricm0727
McCullough, Peter A. ; Beaver, Thomas M. ; Bennett-Guerrero, Elliott ; Emmett, Michael ; Fonarow, Gregg C. ; Goyal, Abhinav ; Herzog, Charles A. ; Kosiborod, Mikhail ; Palmer, Biff F. / Acute and chronic cardiovascular effects of hyperkalemia : New insights into prevention and clinical management. In: Reviews in Cardiovascular Medicine. 2014 ; Vol. 15, No. 1. pp. 11-23.
@article{c858f7dcbfc8478ab6ee6dcc16b5b25f,
title = "Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management",
abstract = "The plasma pool of potassium is a partial reflection of the overall body, transient cellular shifts, and potassium elimination regulated by the kidneys. Potassium concentrations elevating above the upper limit of normal (. 5.0 mEq/L) have become more common in cardiovascular practice due to the growing population of patients with chronic kidney disease and the broad applications of drugs that modulate potassium excretion by either reducing production of angiotensin II (angiotensin-converting enzyme inhibitors, direct renin inhibitors, beta-adrenergic receptor antagonists), blocking angiotensin II receptors (angiotensin receptor blockers), or antagonizing the action of aldosterone on mineralocorticoid receptors (mineralocorticoid receptor antagonists). In addition, acute kidney injury, critical illness, crush injuries, and massive red blood cell transfusions can result in hyperkalemia. Progressively more severe elevations in potassium are responsible for abnormalities in cardiac depolarization and repolarization and contractility. Untreated severe hyperkalemia results in sudden cardiac death. Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects. This review explores hyperkalemia as a complication in cardiovascular patients and highlights new acute, chronic, and preventative oral therapies (patiromer calcium, cross-linked polyelectrolyte, ZS-9) that could potentially create a greater margin of safety for vulnerable patients with combined heart and kidney disease.",
keywords = "Cardiovascular effects of kidney disease, Chronic kidney disease, Hyperkalemia, Potassium concentration",
author = "McCullough, {Peter A.} and Beaver, {Thomas M.} and Elliott Bennett-Guerrero and Michael Emmett and Fonarow, {Gregg C.} and Abhinav Goyal and Herzog, {Charles A.} and Mikhail Kosiborod and Palmer, {Biff F.}",
year = "2014",
doi = "10.3909/ricm0727",
language = "English (US)",
volume = "15",
pages = "11--23",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "1",

}

TY - JOUR

T1 - Acute and chronic cardiovascular effects of hyperkalemia

T2 - New insights into prevention and clinical management

AU - McCullough, Peter A.

AU - Beaver, Thomas M.

AU - Bennett-Guerrero, Elliott

AU - Emmett, Michael

AU - Fonarow, Gregg C.

AU - Goyal, Abhinav

AU - Herzog, Charles A.

AU - Kosiborod, Mikhail

AU - Palmer, Biff F.

PY - 2014

Y1 - 2014

N2 - The plasma pool of potassium is a partial reflection of the overall body, transient cellular shifts, and potassium elimination regulated by the kidneys. Potassium concentrations elevating above the upper limit of normal (. 5.0 mEq/L) have become more common in cardiovascular practice due to the growing population of patients with chronic kidney disease and the broad applications of drugs that modulate potassium excretion by either reducing production of angiotensin II (angiotensin-converting enzyme inhibitors, direct renin inhibitors, beta-adrenergic receptor antagonists), blocking angiotensin II receptors (angiotensin receptor blockers), or antagonizing the action of aldosterone on mineralocorticoid receptors (mineralocorticoid receptor antagonists). In addition, acute kidney injury, critical illness, crush injuries, and massive red blood cell transfusions can result in hyperkalemia. Progressively more severe elevations in potassium are responsible for abnormalities in cardiac depolarization and repolarization and contractility. Untreated severe hyperkalemia results in sudden cardiac death. Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects. This review explores hyperkalemia as a complication in cardiovascular patients and highlights new acute, chronic, and preventative oral therapies (patiromer calcium, cross-linked polyelectrolyte, ZS-9) that could potentially create a greater margin of safety for vulnerable patients with combined heart and kidney disease.

AB - The plasma pool of potassium is a partial reflection of the overall body, transient cellular shifts, and potassium elimination regulated by the kidneys. Potassium concentrations elevating above the upper limit of normal (. 5.0 mEq/L) have become more common in cardiovascular practice due to the growing population of patients with chronic kidney disease and the broad applications of drugs that modulate potassium excretion by either reducing production of angiotensin II (angiotensin-converting enzyme inhibitors, direct renin inhibitors, beta-adrenergic receptor antagonists), blocking angiotensin II receptors (angiotensin receptor blockers), or antagonizing the action of aldosterone on mineralocorticoid receptors (mineralocorticoid receptor antagonists). In addition, acute kidney injury, critical illness, crush injuries, and massive red blood cell transfusions can result in hyperkalemia. Progressively more severe elevations in potassium are responsible for abnormalities in cardiac depolarization and repolarization and contractility. Untreated severe hyperkalemia results in sudden cardiac death. Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects. This review explores hyperkalemia as a complication in cardiovascular patients and highlights new acute, chronic, and preventative oral therapies (patiromer calcium, cross-linked polyelectrolyte, ZS-9) that could potentially create a greater margin of safety for vulnerable patients with combined heart and kidney disease.

KW - Cardiovascular effects of kidney disease

KW - Chronic kidney disease

KW - Hyperkalemia

KW - Potassium concentration

UR - http://www.scopus.com/inward/record.url?scp=84901948477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901948477&partnerID=8YFLogxK

U2 - 10.3909/ricm0727

DO - 10.3909/ricm0727

M3 - Article

C2 - 24762462

AN - SCOPUS:84901948477

VL - 15

SP - 11

EP - 23

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - 1

ER -